Condition: Multiple Myeloma · Sponsor: The First Affiliated Hospital with Nanjing Medical University
The purpose of the study is to compare the efficacy and safety of daratumumab, lenalidomide and dexamethasone (DRd) to that of modified bortezomib, lenalidomide and dexamethasone (VRd-lite), in terms of progression-free survival and minimal residual disease negativity rate in elderly participants with newly diagnosed multiple myeloma.
This description comes directly from the study's public registry record.
Yuanyuan Jin, Doctor · +86-025-68306091 · 827508088@qq.com
Lijuan Chen · +86-025-68306091 · chenljb@126.com
Always discuss trial participation with your own doctor first.
| Changzhou Second People's Hospital | Changzhou, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| Nanjing First People's Hospital | Nanjing, Jiangsu, China | Recruiting |
| Affiliated Hospital of Nantong University | Nantong, Jiangsu, China | Recruiting |
| Taizhou People's Hospital | Taizhou, Jiangsu, China | Recruiting |
| Yancheng First People's Hospital | Yancheng, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06497738